# Lactylation as a metabolic–epigenetic switch: Mechanisms and roles in cancer, sepsis, trauma, inflammation, and tissue repair

**Authors:** David Bar-Or, Kaysie Banton, David Acuna, Jason Williams, Carlos H. Palacio, Christopher Zaw-mon, Raymond Garrett, Tyler Crawley, Daniel Paredes

PMC · DOI: 10.1016/j.bbrep.2026.102507 · 2026-02-16

## TL;DR

Lactate, once seen as a waste product, is now understood to act as a signaling molecule that modifies proteins and influences gene activity, impacting cancer, inflammation, and tissue healing.

## Contribution

This paper reviews how lactylation connects metabolism to epigenetics and immune function, offering new insights into disease mechanisms and potential therapies.

## Key findings

- Lactylation modifies histones and non-histone proteins, linking metabolism to gene regulation.
- Lactylation affects immune cell function, tumor progression, and tissue repair processes.
- Targeting lactylation pathways could lead to new treatments for cancer and inflammatory diseases.

## Abstract

Lactylation, a recently discovered post-translational modification, links cellular metabolism to epigenetic regulation and immune function. Once considered a mere glycolytic byproduct, lactate is now recognized as a signaling metabolite that can shape gene expression and protein activity via histone and non-histone lactylation. This review synthesizes evidence on enzymatic and non-enzymatic mechanisms of lactylation, including lactoyl-CoA-dependent pathways, glyoxalase-mediated routes, and emerging functions of aminoacyl-tRNA synthetases. We highlight lactylation “writers” and “erasers,” stereochemical considerations, and integration with other acyl modifications while explicitly distinguishing well-supported mechanisms from hypothesis-generating findings. Functionally, lactylation influences inflammatory signaling, metabolic reprogramming, and immune cell polarization, providing a conceptual link across sepsis, trauma, autoimmune disease, cancer, and tissue repair. Examples include HMGB1 modification cascades in sepsis, macrophage state transitions in inflammation, fibroblast/angiogenic programs in wound environments, and DNA repair regulation in cancer drug resistance. The context-dependence of lactylation adaptive versus pathological, tumor-promoting versus potentially tumor-restrictive underscores the need for temporal, cell-type, and compartment-specific interpretation. We conclude with methodological constraints, translational feasibility, and key priorities for moving lactylation from a mechanistic bridge to a clinical biomarker and therapeutic axis.

•Lactate acts as a signaling metabolite influencing gene expression via lactylation.•Lactate modulates immune responses via lactylation in macrophages and other cells.•Lactate-driven lactylation influences tumor microenvironment and cancer progression.•Targeting lactylation pathways offers new therapeutic strategies in disease treatment.

Lactate acts as a signaling metabolite influencing gene expression via lactylation.

Lactate modulates immune responses via lactylation in macrophages and other cells.

Lactate-driven lactylation influences tumor microenvironment and cancer progression.

Targeting lactylation pathways offers new therapeutic strategies in disease treatment.

## Linked entities

- **Proteins:** HMGB1 (high mobility group box 1)
- **Chemicals:** lactate (PubChem CID 61503)
- **Diseases:** cancer (MONDO:0004992), autoimmune disease (MONDO:0007179)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, HAGH (hydroxyacylglutathione hydrolase) [NCBI Gene 3029] {aka GLO2, GLO2D, GLX2, GLXII, HAGH1}, RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111] {aka NBSLD, RAD502, hRad50}, KAT5 (lysine acetyltransferase 5) [NCBI Gene 10524] {aka ESA1, HTATIP, HTATIP1, NEDFASB, PLIP, TIP}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}, HCAR1 (hydroxycarboxylic acid receptor 1) [NCBI Gene 27198] {aka FKSG80, GPR104, GPR81, HCA1, LACR1, TA-GPCR}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, NAT10 (N-acetyltransferase 10) [NCBI Gene 55226] {aka ALP, Kre33, NET43}, SIRT2 (sirtuin 2) [NCBI Gene 22933] {aka SIR2, SIR2L, SIR2L2}, HDAC2 (histone deacetylase 2) [NCBI Gene 3066] {aka HD2, KDAC2, RPD3, YAF1}, KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648] {aka GCN5, GCN5L2, PCAF-b, hGCN5}, NBN (nibrin) [NCBI Gene 4683] {aka AT-V1, AT-V2, ATV, NBS, NBS1, P95}, ACSS2 (acyl-CoA synthetase short chain family member 2) [NCBI Gene 55902] {aka ACAS2, ACECS, ACS, ACSA, AceCS1, dJ1161H23.1}, KAT8 (lysine acetyltransferase 8) [NCBI Gene 84148] {aka LIGOWS, MOF, MYST1, ZC2HC8, hMOF}, AARS1 (alanyl-tRNA synthetase 1) [NCBI Gene 16] {aka AARS, CMT2N, DEE29, EIEE29, HDLS2, TTD8}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ATAT1 (alpha tubulin acetyltransferase 1) [NCBI Gene 79969] {aka C6orf134, MEC17, Nbla00487, alpha-TAT, alpha-TAT1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, GLO1 (glyoxalase I) [NCBI Gene 2739] {aka GLOD1, GLYI, HEL-S-74}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TEAD1 (TEA domain transcription factor 1) [NCBI Gene 7003] {aka AA, NTEF-1, REF1, TCF-13, TCF13, TEAD-1}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, YTHDF2 (YTH N6-methyladenosine RNA binding protein F2) [NCBI Gene 51441] {aka CAHL, DF2, HGRG8, NY-REN-2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, MRE11 (MRE11 double strand break repair nuclease) [NCBI Gene 4361] {aka ATLD, HNGS1, MRE11A, MRE11B}, HDAC1 (histone deacetylase 1) [NCBI Gene 3065] {aka GON-10, HD1, KDAC1, RPD3, RPD3L1}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, KAT7 (lysine acetyltransferase 7) [NCBI Gene 11143] {aka HBO1, HBOA, MYST2, ZC2HC7}, HDAC11 (histone deacetylase 11) [NCBI Gene 79885] {aka HD11}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, AARS2 (alanyl-tRNA synthetase 2, mitochondrial) [NCBI Gene 57505] {aka AARSL, COXPD8, LKENP, MT-ALARS, MTALARS}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, RUBCNL (rubicon like autophagy enhancer) [NCBI Gene 80183] {aka C13orf18, KIAA0226L, PACER}
- **Diseases:** heart failure (MESH:D006333), Sepsis (MESH:D018805), brain tumor (MESH:D001932), bladder cancer (MESH:D001749), hepatocellular carcinoma (MESH:D006528), septic shock (MESH:D012772), immune dysregulation (OMIM:614878), colorectal cancer (MESH:D015179), hyperglycemic (MESH:D006944), metastasis (MESH:D009362), rheumatoid arthritis (MESH:D001172), osteoporosis (MESH:D010024), Inflammatory immune diseases (MESH:D007154), infection (MESH:D007239), tumorigenesis (MESH:D063646), acute kidney injury (MESH:D058186), paralysis (MESH:D010243), hypoxic (MESH:D002534), autoimmune disease (MESH:D001327), organ dysfunction (MESH:D009102), gastric cancer (MESH:D013274), metabolic disorders (MESH:D008659), critical illness (MESH:D016638), hyperglycemia (MESH:D006943), fibrosis (MESH:D005355), ocular melanoma (MESH:D008545), glioma (MESH:D005910), Chronic inflammation (MESH:D007249), Trauma (MESH:D014947), shock (MESH:D012769), liver fibrosis (MESH:D008103), Cancer (MESH:D009369)
- **Chemicals:** GSH (MESH:D005978), ATP (MESH:D000255), MGO (MESH:D011765), AMP (MESH:D000249), NAD+ (MESH:D009243), lysine (MESH:D008239), LGSH (-), S-d-lactoylglutathione (MESH:C013585), CoA (MESH:D003065), acyl-CoAs (MESH:D000214), Lactoyl-CoA (MESH:C047009), L- (MESH:D007930), bevacizumab (MESH:D000068258), oxygen (MESH:D010100), pyruvate (MESH:D019289), Lactate (MESH:D019344)
- **Species:** Trypanosoma brucei (species) [taxon 5691], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HEK293T. — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12925563/full.md

---
Source: https://tomesphere.com/paper/PMC12925563